key: cord-0979154-natngnkx
authors: Medetalibeyoglu, Alpay; Catma, Yunus; Senkal, Naci; Ormeci, Asli; Cavus, Bilger; Kose, Murat; Bayramlar, Osman Faruk; Yildiz, Gulcan; Akyuz, Filiz; Kaymakoglu, Sabahattin; Tukek, Tufan
title: The effect of liver test abnormalities on the prognosis of covid-19
date: 2020-09-10
journal: Ann Hepatol
DOI: 10.1016/j.aohep.2020.08.068
sha: 60aad65a176cb02048c40ed47e68aa966d6cb39d
doc_id: 979154
cord_uid: natngnkx

INTRODUCTION: COVID-19 caused by the SARS-CoV-2 continues to spread rapidly across the world. In our study, we aim to investigate the relationship between the liver enzymes on admission (AST, ALT, ALP, GGT) and severity of COVID-19. We evaluated course of disease, hospital stay, liver damage and mortality. MATERIALS AND METHODS: Our study included 614 patients who were hospitalized with the diagnosis of COVID-19 between 03.16.20-05.12.20. Patients with liver disease, hematological and solid organ malignancy with liver metastases were excluded, resulting in 554 patients who met our inclusion criteria. We retrospectively evaluated liver transaminase levels, AST/ALT ratio, cholestatic enzyme levels and R ratio during hospital admission and these were compared in terms of morbidity, mortality and clinical course. RESULTS: Mean age of 554 subjects were 66.21 ± 15.45 years, 328 (59.2%) were men. The mean values of liver enzymes on admission were AST(36.2 ± 33.6 U/L), ALT(34.01 ± 49.34 U/L), ALP(78.8 ± 46.86 U/L), GGT(46.25 ± 60.05 U/L). Mortality rate and need for intensive care unit were statistically significant in subjects that had high ALT-AST levels during their admission to the hospital(p = 0.001). According to the ROC analysis AST/ALT ratio was a good marker of mortality risk (AUC = 0.713:p = 0.001) and expected probability of intensive care unit admission (AUC = 0.636:p = 0.001). R ratio, which was used to evaluate prognosis, showed a poor prognosis rate of 26.5% in the cholestatic injury group, 36.1% in the mixed pattern group and 30% in the hepato-cellular injury group(p 0.001). CONCLUSIONS: ALT-AST elevation and AST/ALT ratio>1 was associated with more severe course and increased mortality in COVID-19.

J o u r n a l P r e -p r o o f A novel type of coronavirus was identified after multiple unexplained cases of pneumonia in Wuhan on December 2019, declared a pandemic by the WHO on 12 March 2020 [1, 2] . Since the first case was reported, many people have been infected and unfortunately many have died all over the world.

Patients infected with corona virus disease 2019 are often admitted to the hospital with cough, shortness of breath, high fever, fatigue, and anosmia. Mortality is due to respiratory failure, for which the rate is approximately 2-3% [3, 4] .

Although the most important clinical manifestations are related to the lung injury, pathological clinical findings can also occur in other organs such as the liver, heart, pancreas and kidneys. This is likely due to multiple organs expressing the main viral entry receptor, called ACE2 receptor (Angiotensin-converting enzyme 2 receptor) [5, 6] . Due to receptor distribution throughout the body, SARS-CoV-2 may infect hepatocytes and bile duct cells and cause the abnormal liver function seen in these patients [5, 24] The abnormality in liver function tests are particularly abnormal in severe COVID-19 cases, and the rate has previously been reported around 14-53%, most often in a hepatocellular pattern [7, 8] .

There are different mechanisms that result in liver damage in patients with COVID-19 infection. A liver biopsy from a case with COVID19 showed moderate microvesicular steatosis and mild lobular and portal activity, consistent with either direct viral infection or drug-induced liver injury; however, hepatocyte viral inclusions were not identified [9] . It has been reported that mortality and need for intensive care may be greater in those with severe liver disease[10,11,12].

Thus far cases of various liver pathologies have been reported, such as acute hepatitis, severe acute hepatitis, and acute-on-chronic liver failure. In this study, we retrospectively 

Throughout March 16, 2020 and May 12, 2020, we retrospectively evaluated the data of 614 patients who had been hospitalized with COVID-19. According to inclusion criteria, a total of 604 patients with COVID-19 pneumonia were included in this study.

All patients had clinical manifestations including fever, respiratory symptoms and a diagnosis of pneumonia based on radiological findings. Patients with liver comorbidities, including hepatitis B virus (HBV), hepatitis C virus (HCV) co-infection, chronic alcohol consumption (>30 g in men and 20 g in women of pure alcohol per day), Wilson's disease, autoimmune hepatitis, other known liver disease and imaging or laboratory results that indicated cirrhosis and evidence of immune suppression, human immunodeficiency virus (HIV) co-infection, and patients diagnosed with malignancy (solitary or hematological) were excluded from the study (60 patients total). (Fig.1) Patient demographics and laboratory findings were evaluated. Laboratory parameters were evaluated according to gender and age groups (<50, 50-65, >65). Epidemiological, clinical, laboratory characteristics, treatment, subjective and objective data were obtained by the hospitalization management system. All subjects underwent serum biochemistry testing on admission, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), bilirubin, procalcitonin (PCT), ferritin, fibrinogen, aPTT (active Partial thromboplastin time), D-dimer, lactate, albumin, C-reactive protein (CRP) and complete blood counts. Enzyme linked immunosorbent assays (ELISA) were used to measure HBsAg, anti-HCV antibodies, and HIV. In these subjects, R ratio was calculated according to this formula; R = (ALT value ÷ ALT Study groups were stratified based on AST-ALT levels (<40 or >40), AST/ALT ratios (<1 or >1) and the R ratio. The prognoses were evaluated according to the AST-ALT levels, AST/ALT, and R ratio (Fig.1) .

A poor prognosis was determined according to intensive care admission, death and diffuse pneumonia.

All patients were isolated and placed on bed rest. They received supportive care including fluid replacement therapy, and all electrolyte imbalances were treated according to clinical situations.

J o u r n a l P r e -p r o o f Blood pressure, pulse and oxygen saturation were monitored twice a day and supplemental oxygen was given to hypoxemic patients.

Since there is no accepted antiviral treatment regimen, patients were treated with a combination of medicines consisting of hydroxychloroquine sulfate, azithromycin, favipravir, tocilizumab and anakinra. Drug choice was based on the medical team's decision and the patients' clinical symptoms.

The specific treatment protocols were defined as Favipravir (1.6 g orally twice daily on day 1 , followed by 600 mg orally twice daily for a total duration of 5 days) Tocilizumab (8 mg/kg intravenously as a single dose) and Anakinra (100 mg subcutaneously twice daily for 7 days) determined according to patients' symptoms, hypoxemia, chest CT findings and acute phase reactants (CRP, Fibrinogen, Ferritin). Antibiotics were used if needed and this decision was based on the patients' healthcare providers discretion.

Quantitative variables are expressed as mean & standard deviation if they contain continuous data. If they contain categorical data, they are expressed as percentage (%) and frequency (n).

Comparison of qualitative variables was analyzed using the Pearson Chi square test.

The normal distribution, which was used to question the presence of parametric data in the data containing the measurement, was examined by Kolmogrov-Smirnov and Curtosis -Skewness Tests. Age showed normal distribution, which could be parametric. A Student's ttest was used to compare parameters including only age.

Kruskal Wallis Test was used for the analysis of continuous and more than two independent non-parametric groups (Bonferroni correction was used when necessary) and Mann Whitney Test was used for post-hoc analysis. Receiver Operating Characteristic (ROC) Curves Dependent groups were handled one by one, ROC curves were drawn and "Area Under the Curve", "Sensitive (sens) and Specificity (spes) of Cut-Off Values" were shown.

Additionally, the optimum cut-off point suggestions were given for the parameters. Patient data that exceeds the cut-off value indicates that it involves a high risk in that parameter. The closer the Area under the Curve (AUC) value is to 100, the better the cut-off points are, in that regard. This study suggested that these cut-off values can be used for these parameters in healthcare facilities, which are considered to include practically similar patients. The results J o u r n a l P r e -p r o o f were evaluated in 95% confidence interval and statistical significance level was defined as p <0.05. The analyzes were performed using IBM SPSS -21 (Statistical Package for Social Sciences, Chicago, IL, USA).

The mean age of 554 COVİD-19 subjects in our study was 66.21 ± 15.45 years, with the youngest patient being 18 and our oldest 96 years old. 30.1 % of patients were over the age of 65. 328 (59.2%) of the patients were men. The mean body mass index was 29.39 ± 4.71. The mean hospital stay of the patients was 16.87 ± 11.6 days. There were 77 (13.9%) patients table 1 and table 2 .

During the first application to the hospital, increased aminotransferase group (n:153/554) (ALT or AST were above >40 IU/L) was 153 patients (27.6%) ( Table 4 ). The rate of alkaline phosphatase or GGT elevation was 4% (Table 9 ).

In patients with increased aminotransferase levels, we detected statistically significant, increased levels of procalcitonin, CRP, ferritin, fibrinogen, D-dimer, lactate and TBILI. In addition, the period of hospital stay was longer in these patients (p=0.048). Albumin and lymphocyte values were statistically significant and lower in these patients. The age distribution of both groups was not significantly different ( Table 3) .

The rates of specific treatment for individuals who had increased AST-ALT levels (58.2%) were observed to be higher than those with normal AST-ALT levels (33.9%) (p=0.001).

( Table 4) The rates of intensive care unit hospitalization (22.9%) in individuals with increased AST-ALT levels were observed to be higher compared to those with normal AST and ALT (10.5%) (p=0.001). (Table 4) J o u r n a l P r e -p r o o f Moderate and severe pneumonia according to CT findings were observed in the elevated aminotransferases group (63.8%) compared to the normal aminotransferases group (43.8%).

(p=0.001). (Table 4) The rate of mortality was higher in the elevated aminotransferases group (13.7%) compared to the normal aminotransferases group (4.7%). (p=0.001). (Table 4) Clinical and laboratory data was compared based on gender. Mean AST, ALT, GGT and TBILI levels were statistically significantly higher in men compared to women.( Table-5 

Subjects were divided into two groups according to whether the AST/ALT ratio was greater than 1. 53.0% of the patients who had AST/ALT ratio > 1 were male (p=0.001) ( Table 7) .

Subjects with increased AST/ALT ratio >1 had a statistically significant increased levels of LDH, CRP, aPTT, fibrinogen, and D-dimer . In the group of AST/ALT ratio >1 the GGT, albumin and lymphocyte levels were lower than the group of AST/ALT ratio <1 (Table 6) .

Several studies have suggested that low albumin levels on hospital admission can be used as a marker of severity of COVID-19 [25, 26].

In the AST / ALT >1 group, the rates of intensive care unit admission (16%) are higher than in the AST/ALT <1 group (9.2%) (p=0.033). Additionally, in the AST / ALT> 1 (52.5%) group, the severity of pneumonia is higher than the AST / ALT <1 (41.4%) group (p = 0.016) (Table 7) .

ROC analysis was used to determine clinical conditions according to AST/ALT ratio and if this ratio could be used as a candidate marker. It was observed that the AUC (Area under the Curve) value under the ROC curve with AST/ALT ratio parameter was also statistically significant in the analyses on mortality, intensive care unit hospitalization, and severity of pneumonia. It was observed that AST/ALT ratio was the best marker of mortality risk (AUC=0.713 / p=0.001); severity of pneumonia (AUC=0.577 / p=0.002) and expected probability of intensive care unit admission (AUC=0.636 / p=0.001) according the ROC analysis. There were no significant differences in specific treatment, hypertension, diabetes mellitus, asthma or COPD and coronary heart disease ( Fig.2) (Table 8) .

In the ROC curve analysis, the optimum cut-off points of mortality risk, severity of pneumonia and probability of admission to expected intensive care unit were respectively 1.65 (sens:0.575 / spes:0.823); 1.55 (sens:0.649 / spes:0.604) and 1.26 (sens:0.610 / spes:0.556). When we look at the AUC; mortality was the strongest parameter among the cut off values. If the AST / ALT ratio exceeds 1.65 in COVID-19 patients, the risk of death appears to be very high (Fig.2) (Table 8) .

Outcomes Subjects were evaluated in two seperate groups according to their prognosis. Poor prognosis was defined as an event of exitus, admission to the intensive care unit and/or meeting criteria for severe pneumonia. The prognosis of subjects was evaluated according to the R ratio (R ratio < 2, 2-5 and >5).

Poor prognosis rate was 26.5% in the cholestatic injury group (R<2), 36.1% in the mixed injury pattern group (R:2-5) and 30% in the hepato-cellular injury group (R>5) (p 0.001) (Table 9 ).

Patients with ALP > 1.5 x ULN and/or GGT> 3 x ULN were considered as elevated cholestatic liver enzyme group that had poor prognosis rate of 52.4% , while in the normal cholestatic liver enzyme group, the poor prognosis rate was 19.5% (p 0.001) ( Table 9 ).

Patients were also divided into 3 groups according to liver transaminase elevation rates: minimal (n=112 patients), mild (n=35 patients) and severe (acute hepatitis) (n=6 patients) which were defined as a liver transaminase elevation <2 times ULN, <5 times ULN , > 5 times ULN, respectively. Poor prognosis rate was 33.9% in patients with minimal elevations in the liver transaminases, 28.6% in mild group and 66.7% in the severe (acute hepatitis) group.(p 0.001)( Table-9 ) [13] . We defined aminotransferase levels over 15 times ULN as severe acute liver injury. There were no patients with severe acute liver injury included in our study.

J o u r n a l P r e -p r o o f COVID 19 pneumonia is a critical condition that often occurs at an advanced age and more predominantly in men [16] . In our study, most subjects were male and about 30% of the cases were in patients over 65 years of age. Some degree of liver damage was observed in the vast majority of subjects, especially in patients with severe or critical illness. In our study, we have seen elevated markers of AST and ALT most often with 4% (n:21) of our patients who had elevated cholestatic enzymes. Due to this observation in our study, we have decided to investigate this relationship and to see if a correlation exists between AST-ALT elevations and COVID-19 disease. ACE2 receptor can be one of the many receptors that play a role in liver damage seen in COVID-19. Further studies may show different hepatocyte receptors that play a role in liver damage due to COVID-19. This may also suggest that the systemic hyperinflammatory state is the main responsible mechanism for the elevation in liver enzymes.

However, there is little data on the prognostic importance of liver test abnormalities.

Recently, increasing evidence has highlighted the close relationship of abnormal liver biochemistries with severity of COVID-19. In our study, we excluded patients with chronic liver diseases to allow us to confidently attribute acute rises in liver enzymes solely to the SARS-CoV2 virus.

In the report by Zhenyu Fan et al, 148 COVID cases were evaluated. In one third of the cases there were increased aminotransferases levels associated with duration of hospital stay.

Patients with abnormal liver functions were more likely to be male, and had higher levels of procalcitonin and CRP [10].

In another cohort of 1099 patients with COVID-19 from China, the mean levels of serum ALT, AST, and bilirubin in severe or critical cases were significantly higher than those in control cases. They noted that patients with severe pneumonia were more likely to develop abnormal aminotransferase levels as compared with those with mild and moderate disease [18] . We found that patients with increased aminotransferases (AST and/or ALT above 40), Previous studies also reported that AST elevations are more frequent than ALT in severe patients upon admission [18, 19] . AST is not a specific marker for liver damage and AST elevations for disease severity suggest immune-mediated inflammation may play a critical role in liver impairment in patients with severe COVID-19. When the AST/ALT ratio is higher than 1, the possibility of its source being cardiac, muscle, or other tissue types should be considered as well [22] .

In our study, we stratified subjects into groups based on whether the AST/ALT value was greater or less than 1. In COVID-19 pneumonia, we found that the AST/ALT>1 was the best predictor for requiring hospitalization in the intensive care unit.

In our study, we evaluated the relationship between the R value and subject prognosis. On evaluation of the prognosis according to the R value in the group with increased liver enzymes, the prognosis rate of cholestatic patern (R<2) group was 26.5%; 36.% in the mixed injury patern group (R:2-5) and 30.0% in the hepato-cellular injury group (R>5) (p 0.001). In summary, elevations of aminotransferases correlated with a poorer prognosis. The importance of our study is to establish the relationship between Aminotransferase levels on admission and COVID-19 disease severity by using the AST/ALT ratio to determine prognosis and requirement for hospitalization. We suggest that this novel data be used by clinicans in order to group patients more efficiently.

This study has its limitations. This was a single-centered study without collaboration from other institutions. The number of patients who met our criteria could have been larger. AST-ALT increase and AST/ALT ratio (>1) can be due to COVID-19 or may have been affected J o u r n a l P r e -p r o o f 

Clinical features of patients with 2019 novel coronavirus in Wuhan

Chinese Center for Disease Control and Prevention Distribution of new coronavirus pneumonia

Acknowledgment: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Thanks to Daniel Gauvin for English editing.